It promotes proliferation and inhibits apoptosis in AML and chronic myeloid leukemia (CML) cells by targeting CTDSPL and TRIB2 (Khalaj et al., 2017; Zhang et al., 2013). Here, TRIB2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.